| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics |
| 02 Jul 2026 |
8-K: Termination of a Material Definitive Agreement
On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement with Terreno Park Union City LLC to terminate the Company’s lease for approximately 94,046 rentable square feet at 33498 Central Avenu... |
| 29 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
On behalf of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), I am pleased to invite you to join the Company as Chief Financial Officer, reporting to the Company’s Chief Executive Officer. Your primary work location will be Thousan... |
| 29 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
to attract and retain the best available personnel for positions of substantial responsibility, |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 |
| 11 Mar 2026 |
8-K: Results of Operations and Financial Condition
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 |
| 05 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
On March 4, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with Alnylam Pharmaceuticals, Inc. (“Alnylam”), pursuant to which the parties agreed to a research collabo... |
| 30 Jan 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Departure/Election of Directors or Officers; Compensation
Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company... |
| 02 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 31, 2025, in connection with his retirement, David Goeddel submitted his resignation from the board of directors (the “Board”) of Tenaya Therapeutics, Inc. (the “Company”) and as a member of all committees of the Board, effec... |
| 12 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
As Representatives of the several Underwriters named in Schedule I hereto |
| 11 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients |
| 07 Nov 2025 |
8-K: Other Events
The U.S. Food and Drug Administration (“FDA”) has placed a clinical hold on MyPEAKTM-1, Tenaya Therapeutics, Inc.’s (“Tenaya”) Phase 1b/2a clinical trial evaluating TN-201 in MYBPC3-associated hypertrophic cardiomyopathy, requesting an a... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Enrollment Complete in Cohorts 1 and 2 of MyPEAKTM-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts |
| 30 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Tenaya Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on May 28, 2025. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. Voting r... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification |
| 18 Apr 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On April 15, 2025, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of t... |
| 28 Mar 2025 |
8-K: Costs Associated with Exit or Disposal Activities
On March 27, 2025, Tenaya Therapeutics, Inc. (“Tenaya”) approved the implementation of a restructuring plan (the “Restructuring Plan”) to further focus company resources on generating data from MyPEAKTM-1, evaluating TN-201 as a gene the... |
| 10 Mar 2025 |
8-K: Results of Operations and Financial Condition
Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy |
Loading...